Scarica l'app Stockscreener
4.11
3.29%
-0.14
Dopo l'orario di chiusura:
4.11
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MYGN Giù?
Forum
Previsione
Frazionamento azionario
Myriad Genetics Inc Borsa (MYGN) Ultime notizie
Price T Rowe Associates Inc. MD Cuts Stock Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Myriad genetics lowers 2025 revenue guidance by $35M amid GeneSight challenges - MSN
Robust Growth in Preventive Healthcare Technologies - openPR.com
Myriad Genetics, Inc. (NASDAQ:MYGN) Q1 2025 Earnings Call Transcript - MSN
Myriad Genetics (NASDAQ:MYGN) Cut to “Equal Weight” at Wells Fargo & Company - Defense World
StockNews.com Downgrades Myriad Genetics (NASDAQ:MYGN) to Hold - Defense World
Lacklustre Performance Is Driving Myriad Genetics, Inc.'s (NASDAQ:MYGN) 48% Price Drop - simplywall.st
Myriad Genetics, Inc. (MYGN): Among Billionaire Larry Robbins’ Stock Picks with Huge Upside Potential - Insider Monkey
Securities Fraud Investigation Into Myriad Genetics, Inc. (MYGN) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm - Benzinga
Myriad Genetics Shares Drop After Downgrade From Wolfe Research - marketscreener.com
Global Consumer Genomics Market Set to Witness Significant - openPR.com
Myriad Genetics (MYGN) Downgraded as Price Target Significantly Lowered | MYGN Stock News - GuruFocus
Down -49.47% in 4 Weeks, Here's Why Myriad (MYGN) Looks Ripe for a Turnaround - Yahoo Finance
Myriad Genetics Shares Tank 41% On Analyst Downgrades, Weaker Guidance: Yet Retail Investors Remain Bullish - Investing.com India
Securities Fraud Investigation Into Myriad Genetics, Inc. (MYGN) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz | FinancialContent - FinancialContent
What Analysts Are Saying About Myriad Genetics Stock - Benzinga
Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology - GlobeNewswire
Why Myriad Genetics (MYGN) Stock Is Down Today - Yahoo Finance
Goldman Sachs Adjusts Price Target for MYGN, Maintains Buy Rating | MYGN Stock News - GuruFocus
Raymond James Reiterates 'Outperform' But Lowers Price Target for MYGN | MYGN Stock News - GuruFocus
Future-Proofing Growth of Direct-to-consumer Genetic Health - openPR.com
Myriad Genetics (MYGN) Target Price Reduced by Analyst Amid Challenges | MYGN Stock News - GuruFocus
UBS Adjusts Price Target on Myriad Genetics to $7 From $16, Maintains Neutral Rating - marketscreener.com
Earnings call transcript: Myriad Genetics Q1 2025 Misses Revenue Expectations By Investing.com - Investing.com South Africa
UBS Adjusts Price Target for Myriad Genetics (MYGN) Following Q1 Results | MYGN Stock News - GuruFocus
MYGN Q1 Earnings Top Estimates, Stock Down on Weak 2025 Outlook - Yahoo Finance
Raymond James Adjusts Price Target for Myriad Genetics (MYGN) | MYGN Stock News - GuruFocus
Wells Fargo Downgrades Myriad Genetics to Equalweight From Overweight, Adjusts Price Target to $6 From $22 - marketscreener.com
Myriad Genetics (MYGN) Faces Downgrade Amid Growth Concerns | MY - GuruFocus
Myriad Genetics (MYGN) Faces Downgrade Amid Growth Concerns | MYGN Stock News - GuruFocus
Myriad Genetics Inc (MYGN) Q1 2025 Earnings Call Highlights: Navigating Revenue Challenges and ... - Yahoo Finance
Myriad Genetics Inc (MYGN) Q1 2025 Earnings Call Highlights: Navigating Revenue Challenges and Strategic Growth Initiatives - GuruFocus
Myriad Genetics Reports Mixed Q1 2025 Results - TipRanks
Myriad Genetics, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:MYGN) - Seeking Alpha
Myriad Genetics Q1 2025 Earnings Call Transcript - MarketBeat
Myriad: Q1 Earnings Snapshot - MySA
Earnings call transcript: Myriad Genetics Q1 2025 Misses Revenue Expectations - Investing.com Nigeria
Myriad (MYGN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Myriad Genetics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Myriad Genetics (NASDAQ:MYGN) Misses Q1 Sales Targets, Stock Drops 14.5% - Yahoo Finance
Myriad Genetics Inc Reports Q1 2025 Earnings: EPS of $(0.03) Bea - GuruFocus
Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Myriad Genetics Q1 2025 slides: Revenue declines 3% as company slashes guidance - Investing.com
Myriad Genetics (MYGN) Lowers 2025 Guidance Following Revenue Miss | MYGN Stock News - GuruFocus
Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance - The Manila Times
Myriad Genetics Reports 3% Decline in Q1 2025 Revenue; Updates Financial Guidance for Full-Year - Nasdaq
Earnings Flash (MYGN) Myriad Genetics Posts Q1 Adjusted EPS $-0.03, vs. FactSet Est of $-0.05 - marketscreener.com
Myriad Genetics Q1 25 Earnings Conference Call At 4:30 PM ET - Nasdaq
PARP Inhibitor Biomarkers Market Top PlayersMyriad Genetics, - openPR.com
Myriad Genetics Quarterly Earnings Preview: What to ExpectNews and Statistics - IndexBox
What To Expect From Myriad Genetics’s (MYGN) Q1 Earnings - Yahoo Finance
Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help - Hometown Stations
Press Release Distribution & PR Platform - ACCESS Newswire
Myriad Genetics: Significantly Undervalued With Profitability In Sight - Seeking Alpha
Molecular Diagnostics Market to Witness Remarkable Growth with - openPR.com
0.80%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):